BrainChild Bio targets deadly pediatric brain cancer with $116M series A
BrainChild Bio’s lead asset BCB-276 is in pivotal development for diffuse intrinsic pontine glioma, a rare and fatal brain tumor that affects around 300 children in the U.S. every year.
comments(0)
5-min edit window · permanent after that